This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
NOTICE PAPER NO. 3151
NOTICE OF QUESTION FOR ORAL ANSWER
FOR THE SITTING OF PARLIAMENT ON OR AFTER 15 OCTOBER 2024
Name and Constituency of Member of Parliament
Mr Gerald Giam Yean Song
MP for Aljunied GRC
Question No. 6734
To ask the Minister for Health given that the moratorium on Integrated Shield Plan premium increases has ended, whether the Ministry will be providing guidance to insurance companies on (a) the quantum and range of increases in premiums they may make; and (b) set the permissible frequency and quantum of future increases.
Answer
1 When the Government implemented the Cancer Drug List (CDL) policy from 1 Sep 2022, the Ministry of Health (MOH) discussed with the insurers, who agreed to implement a two-year moratorium on Integrated Shield Plan (IP) premium increases from 2 September 2022 to 31 August 2024. This was in view of the CDL being a significant policy change to reduce the cost of cancer drugs, and hence claims, and to better support policyholders through the transition period.
2 MOH currently regulates the key parameters of IPs, such as the co-payment and deductible, to ensure these products can function sustainably as a key part of our healthcare financing system. However, IPs remain private products. Insurance companies compete in a competitive market and the products need to remain commercially viable. Therefore, MOH’s general practice is not to regulate aspects such as premiums, service quality, or underwriting, which are integral to market competition. The quantum and frequency of premium revisions are subject to insurers’ actuarial and commercial considerations.
3 MOH encourages Singaporeans to make informed decisions about health insurance purchases, taking into consideration their preferred healthcare choices and whether they would be able to continue paying premiums in future. We will continue to publish information on IP premiums and coverage to facilitate consumers in making informed decisions.
4 Regardless of IP coverage, all Singapore Citizens and Permanent Residents are covered by MediShield Life, which will be adequate for subsidised care in public hospitals.